{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:06:53Z","timestamp":1792130813175,"version":"4.4.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.jconrel.2011.10.036","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T18:04:49Z","timestamp":1320775489000},"page":"283-289","source":"Crossref","is-referenced-by-count":33,"title":["Complement system and the brain: Selected pathologies and avenues toward engineering of neurological nanomedicines"],"prefix":"10.1016","volume":"161","author":[{"given":"Barbara","family":"Lettiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina J.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Christy","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Moein","family":"Moghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2011.10.036_bb0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","article-title":"Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective","volume":"52","author":"Moghimi","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1096\/fj.04-2747rev","article-title":"Nanomedicine: current status and future prospects","volume":"19","author":"Moghimi","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pneurobio.2009.05.002","article-title":"Nanotechnological applications for the treatment of neurodegenerative disorders","volume":"88","author":"Modi","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.phrs.2010.02.004","article-title":"Nano-interventions for neurodegenerative disorders","volume":"62","author":"Fernandes","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.nano.2011.05.001","article-title":"Bionanotechnologies for treatment and diagnosis of Alzheimer's disease","volume":"7","author":"Moghimi","year":"2011","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.nano.2011.03.008","article-title":"Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues","volume":"7","author":"Brambilla","year":"2011","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0035","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0040","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1021\/ac102045x","article-title":"New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-\u03b2 peptide","volume":"82","author":"Brambilla","year":"2010","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1523\/JNEUROSCI.23-01-00029.2003","article-title":"Novel therapeutic approach for the treatment of Azheimer's disease by peripheral administration of agents with an affinity to \u03b2-amyloid","volume":"23","author":"Matsuoka","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0050","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-\u03b2 by circulating lipoprotein receptors","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0055","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","article-title":"Lipid-based nanoparticles with high binding affinity for amyloid beta 1\u201342 peptide","volume":"31","author":"Gobbi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0060","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1016\/j.biomaterials.2011.04.020","article-title":"The binding affinity of anti-A\u03b21\u201342 MAb-decorated nanoliposomes to A\u03b21\u201342 peptides in vitro and to amyloid deposits in post-mortem tissue","volume":"32","author":"Canovi","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0065","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.addr.2011.06.005","article-title":"Complement in health and disease","volume":"63","author":"Carroll","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0070","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.molimm.2006.03.007","article-title":"Role of complement in neurodegeneration and neuroinflammation","volume":"44","author":"Bonifati","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0080","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.molimm.2011.04.003","article-title":"Complement in the brain","volume":"48","author":"Veerhuis","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/NEN.0b013e3181996688","article-title":"The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain","volume":"68","author":"Griffiths","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0090","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0095","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/00005072-199605000-00010","article-title":"Role of complement in the aetiology of Pick's disease?","volume":"55","author":"Singhrao","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0100","doi-asserted-by":"crossref","first-page":"8727","DOI":"10.4049\/jimmunol.181.12.8727","article-title":"The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis","volume":"181","author":"Woodruff","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2010.04.003","article-title":"Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead","volume":"146","author":"Moghimi","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0110","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.addr.2011.06.002","article-title":"Material properties in complement activation","volume":"63","author":"Moghimi","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jnr.490270106","article-title":"Chemotaxis by CNS macrophages, the microglia","volume":"27","author":"Yao","year":"1990","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0120","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1471-4159.2008.05668.x","article-title":"The complement cascade: Yin-Yang in neuroinflammation\u2013neuro-protection and -degeneration","volume":"107","author":"Alexander","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0005-2736(80)90417-4","article-title":"Influence of temperature on complement-dependent immune damage to liposomes","volume":"600","author":"Alving","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0130","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.167.5.2861","article-title":"Human IgA activates the complement system via the mannan-binding lectin pathway","volume":"167","author":"Roos","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0135","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2005.12.039","article-title":"CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens","volume":"124","author":"Helmy","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0140","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI28622","article-title":"Bypassing complement: evolutionary lessons and future implications","volume":"116","author":"Atkinson","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0145","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI25982","article-title":"Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2","volume":"116","author":"Selander","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0150","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0162-3109(00)80302-1","article-title":"Complement components of the innate immune system in health and disease in the CNS","volume":"49","author":"Gasque","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1471-4159.2009.06494.x","article-title":"C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production","volume":"112","author":"Fraser","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0165","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/stem.225","article-title":"Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells","volume":"27","author":"Shinjyo","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0460","series-title":"Complement Regulatory Proteins","first-page":"82","article-title":"Regulation in the activation pathways\u2014membrane RCA proteins","author":"Morgan","year":"1999"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0465","series-title":"Regulation in the Terminal Pathway\u2014Membrane Regulators of the Terminal Pathway in Complement Regulatory Proteins","first-page":"153","author":"Morgan","year":"1999"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.imbio.2007.04.001","article-title":"C1q binding and complement activation by prions and amyloids","volume":"212","author":"Sim","year":"2007","journal-title":"Immunobiology"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0185","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1086476","article-title":"CD46 in meningococcal disease","volume":"301","author":"Johansson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0190","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4049\/jimmunol.143.3.923","article-title":"Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2\/CD21) in mouse and human cells","volume":"143","author":"Carel","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0195","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/00002030-199612000-00004","article-title":"Acquisition of host cell-surface-derived molecules by HIV-1","volume":"10","author":"Frank","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00002030-199501000-00003","article-title":"Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1","volume":"9","author":"Stoiber","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0470","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/NBHIV.S19969","article-title":"Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS","volume":"3","author":"Singh","year":"2011","journal-title":"Neurobehav. HIV Med."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0215","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neurobiolaging.2006.03.013","article-title":"NSAIDs and Alzheimer's disease: epidemiological, animal and clinical studies","volume":"28","author":"McGeer","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0475","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature06616","article-title":"Rapidappearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease","volume":"451","author":"Meyer-Luehmann","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0480","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.4049\/jimmunol.152.10.5050","article-title":"Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain","volume":"152","author":"Jiang","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0230","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.4049\/jimmunol.167.11.6374","article-title":"Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions","volume":"167","author":"Tacnet-Delorme","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0169-328X(00)00149-2","article-title":"Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain","volume":"81","author":"Strohmeyer","year":"2000","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0240","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.wad.0000165506.60370.94","article-title":"Complement activation in very early Alzheimer's disease","volume":"19","author":"Zanjani","year":"2005","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0245","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0002-9440(10)65340-0","article-title":"Up-regulated production and activation of the complement system in Alzheimer's disease brain","volume":"154","author":"Yasojima","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0250","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","article-title":"Treatment with a C5aR antagonist decrease pathology and enhances behavioral performance in murine models of Alzheimer's disease","volume":"183","author":"Fonseca","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0006-8993(98)00346-1","article-title":"Induced expression of neuronal membrane attack complex (MAC) and cell death by beta-amyloid peptide","volume":"796","author":"Shen","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0260","first-page":"1","article-title":"Human protectin (CD59), an 18,000\u201320,000MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers","volume":"71","author":"Meri","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0265","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1523\/JNEUROSCI.20-20-07505.2000","article-title":"Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease","volume":"20","author":"Yang","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0270","doi-asserted-by":"crossref","first-page":"10837","DOI":"10.1073\/pnas.162350199","article-title":"Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice","volume":"99","author":"Wyss-Coray","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0275","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1523\/JNEUROSCI.0829-08.2008","article-title":"Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia\/macrophage phenotype in amyloid precursor protein transgenic mice","volume":"28","author":"Maier","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0280","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00427222","article-title":"Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins","volume":"84","author":"Yamada","year":"1992","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0285","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1096\/fj.05-5814com","article-title":"Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration","volume":"20","author":"Woodruff","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0290","doi-asserted-by":"crossref","first-page":"49782","DOI":"10.1074\/jbc.M206448200","article-title":"Complement activation in chromosome 13 dementias, Similarities with Alzheimer's disease","volume":"277","author":"Rostagno","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/08982100802309552","article-title":"Liposome-mediated triggering of complement cascade","volume":"18","author":"Moghimi","year":"2008","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0485","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0076-6879(03)73010-9","article-title":"The interaction of liposomes with the complement system: in vitro and in vivo assays","volume":"373","author":"Szebeni","year":"2003","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1011054123304","article-title":"Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups","volume":"18","author":"Moghimi","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v15.i1.20","article-title":"The interaction of liposomes with the complement system","volume":"15","author":"Szebeni","year":"1998","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0315","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1042\/bst0120342","article-title":"Natural antibodies against phospholipids and liposomes in human","volume":"12","author":"Alving","year":"1984","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0320","first-page":"441","article-title":"Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atheroschlerosis and autoimmunity","volume":"10","author":"Alving","year":"1991","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0325","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0005-2736(94)90231-3","article-title":"Liposome\u2013complement interactions in rat serum: implications for liposome survival studies","volume":"1191","author":"Devine","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0330","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0005-2736(99)00013-9","article-title":"C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14\u201326 of the human C1qA chain in a sequence independent manner","volume":"1418","author":"Bradley","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0335","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1021\/bi990480a","article-title":"Unusual electrostatic effects on binding to C1q to anionic liposomes: role of anionic phospholipid domains and their line tension","volume":"38","author":"Bradley","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0340","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.146.12.4234","article-title":"The role of surface charge in the activation of the classical and alternative pathway of complement by liposomes","volume":"146","author":"Chonn","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0345","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.4049\/jimmunol.135.4.2695","article-title":"Antibody-independent activation of C1, the first component of complement, by cardiolipin","volume":"135","author":"Kovacsovics","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0350","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/oxfordjournals.jbchem.a133617","article-title":"Reactivity of human C-reactive protein with positively charged liposomes","volume":"90","author":"Tsujimoto","year":"1981","journal-title":"J. Biochem."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0355","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.4049\/jimmunol.126.5.1820","article-title":"Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement","volume":"126","author":"Volanakis","year":"1981","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0360","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0014-5793(86)80350-7","article-title":"Inhibition of serum complement haemolytic activity by lipid vesicles containing phosphatidylserine","volume":"197","author":"Comis","year":"1986","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0365","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jbiotec.2010.08.252","article-title":"The interaction of complement system with abeta-binding liposomes: towards engineering of safer vesicles for the management of Alzheimer's disease","volume":"150","author":"Andersen","year":"2010","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0490","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.4049\/jimmunol.128.3.1302","article-title":"Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase","volume":"128","author":"Moore","year":"1982","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0375","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0163-7827(03)00033-X","article-title":"Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties","volume":"42","author":"Moghimi","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0380","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1096\/fj.06-6186fje","article-title":"Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production","volume":"20","author":"Moghimi","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2011.05.010","article-title":"Transport of drugs across the blood-brain barrier by nanoparticles","author":"Wohlfart","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0390","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2009.03.002","article-title":"Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons","volume":"137","author":"Zensi","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0395","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1021\/nn101990a","article-title":"Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering","volume":"4","author":"Hamad","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0400","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1166\/jnn.2006.406","article-title":"Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption","volume":"6","author":"Al-Hanbali","year":"2006","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0405","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2006.12.012","article-title":"Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain","volume":"118","author":"Kreuter","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2011.10.036_bb0410","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1016\/S0021-9258(18)53740-6","article-title":"Interaction between apolipoprotein-A-I and apolipoprotein-A-II and the membrane attack complex of complement\u2014affinity of the apoproteins for polymeric-C9","volume":"268","author":"Hamilton","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0415","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.1073\/pnas.1100930108","article-title":"Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing","volume":"108","author":"Al-Jamal","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0420","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1016\/j.molimm.2008.05.020","article-title":"Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover","volume":"45","author":"Hamad","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0425","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.addr.2011.05.012","article-title":"Complement activation by carbon nanotubes","volume":"63","author":"Rybak-Smith","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0430","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nnano.2010.109","article-title":"Complement monitoring of carbon nanotubes","volume":"5","author":"Moghimi","year":"2010","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0435","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0440","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0445","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12017-009-8085-y","article-title":"The role of the complement system and the activation fragment C5a in the central nervous system","volume":"12","author":"Woodruff","year":"2010","journal-title":"Neuromolecular Med."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0450","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1042\/CS20020362","article-title":"Beyond lysis: how complement influences cell fate","volume":"104","author":"Cole","year":"2003","journal-title":"Clin. Sci."},{"key":"10.1016\/j.jconrel.2011.10.036_bb0455","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ab.2006.11.028","article-title":"Modification of the Stewart biphasic colorimetric assay for stable and accurate quantitative determination of Pluronic and Tetronic block copolymers for application in biological systems","volume":"361","author":"Al-Hanbali","year":"2007","journal-title":"Anal. Biochem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911010297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911010297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T14:44:45Z","timestamp":1713105885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365911010297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0168365911010297"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2011.10.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}